Danuglipron DANU

An experimental weight-loss pill (rather than an injection) that was in human trials for obesity and diabetes. It caused real weight loss in trials, but the program was stopped after a participant developed liver damage, ending development of this version of the drug.

Also known as PF-06882961

Effects Lose fat

Routes Oral

Legal status Unapproved / investigational

WADA Not listed

3D Molecular Structure of C₃₁H₃₀FN₅O₄

Drag to rotate · scroll to zoom

Chemistry

Formula: C31H30FN5O4
Molar mass: 555.6
CAS: 2230198-02-2
PubChem CID: 134611040

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial dosing under evaluation

Reported range Phase II/III trials: 40-120 mg twice daily (oral)

Route Oral

Frequency Twice daily

Duration Trial durations of up to a year

Investigational oral GLP-1 receptor agonist (Pfizer); formulation and dosing were still being optimized as of early 2026 after earlier tolerability issues. Not an approved product.

Where this comes from Published Phase II/III clinical trial data (Pfizer)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.